Evidence map›Paper›PMID 24179159›Full record

ArticleScience (New York, N.Y.)2013

Crystal structure of a soluble cleaved HIV-1 envelope trimer.

Jean-Philippe Julien, Albert Cupo, Devin Sok, Robyn L Stanfield, Dmitry Lyumkis, Marc C Deller, Per-Johan Klasse, Dennis R Burton, Rogier W Sanders, John P Moore and 2 more

Open access · greenAbstract read
In one paragraph

Article in Science (New York, N.Y.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 639 papers.

0numbers the graph read from it
0cells of the map it votes in
639citing papers in PubMed
48.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

639 citing papers in PubMed, 821 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. ACS central science · 2025
    Article
  19. Article
  20. Article

579 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Jean-Philippe JulienDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Albert Cupo
Devin Sok
Robyn L Stanfield
Dmitry Lyumkis
Marc C Deller
Per-Johan Klasse
Dennis R Burton
Rogier W Sanders
John P Moore
Andrew B Ward
Ian A Wilson
Cornell University · USScripps Research Institute · USInternational AIDS Vaccine Initiative · USJoint Center for Structural Genomics · US

Funding

Support Component D/Vaccine Discovery, Concept to ClinicUM1AI100663 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BAROUCH, DAN H. · 2012 to 2018
$131.5M
Structure Determination Core at SSRLU54GM094586 · NIGMS · SCRIPPS RESEARCH INSTITUTE, THE · PI WILSON, IAN A · 2010 to 2014
$40.1M
ZWITTERION SURFACTANT DDMAB FOR IMPROV STABIL OF PROTEINP41RR001209 · NCRR · STANFORD UNIVERSITY · PI GONZALEZ, ANA M · 1985 to 2011
$38.9M
Trimer Production and Immunogenicity TestingP01AI082362 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI MOORE, JOHN P · 2009 to 2014
$16.0M
TRD #3: An automated and streamlined pipeline for in-situ molecular microscopyP41GM103310 · NIGMS · SCRIPPS RESEARCH INSTITUTE, THE · PI DE MARCO, ALEX, KIEFT, JEFFREY S · 2012 to 2021
$14.7M
NEUTRALIZATION OF PRIMARY HIV1 VIRUSESR37AI036082 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI MOORE, JOHN P · 1998 to 2017
$7.0M
HUMAN ANTIBODIES TO HIV-1 BY REPERTOIRE CLONINGR01AI033292 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 1992 to 2013
$5.9M
Structural Biology of HIV-1 Neutralizing Antibody Targets for Vaccine DesignR01AI084817 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI WILSON, IAN A · 2009 to 2013
$3.2M
CIHRNCI NIH HHS Y1-CO-1020NCRR NIH HHS P41 RR001209NCRR NIH HHS P41RR001209NIAID NIH HHS P01 AI082362NIAID NIH HHS P01 AI82362NIAID NIH HHS R01 AI033292NIAID NIH HHS R01 AI084817NIAID NIH HHS R01 AI33292NIAID NIH HHS R37 AI036082NIAID NIH HHS R37 AI36082NIAID NIH HHS UM1 AI100663NIGMS NIH HHS GM103310NIGMS NIH HHS P41 GM103310NIGMS NIH HHS U54 GM094586NIGMS NIH HHS Y1-GM-1104
6 · The paper itself

Abstract

HIV-1 entry into CD4(+) target cells is mediated by cleaved envelope glycoprotein (Env) trimers that have been challenging to characterize structurally. Here, we describe the crystal structure at 4.7 angstroms of a soluble, cleaved Env trimer that is stabilized and antigenically near-native (termed the BG505 SOSIP.664 gp140 trimer) in complex with a potent broadly neutralizing antibody, PGT122. The structure shows a prefusion state of gp41, the interaction between the component gp120 and gp41 subunits, and how a close association between the gp120 V1/V2/V3 loops stabilizes the trimer apex around the threefold axis. The complete epitope of PGT122 on the trimer involves gp120 V1, V3, and several surrounding glycans. This trimer structure advances our understanding of how Env functions and is presented to the immune system, and provides a blueprint for structure-based vaccine design.

Indexed as

Antibodies, NeutralizingAntibodies, ViralCrystallography, X-Rayenv Gene Products, Human Immunodeficiency VirusHIV Envelope Protein gp120HIV Envelope Protein gp41HumansProtein MultimerizationProtein Structure, QuaternaryRecombinant ProteinsSolubilityAntibodies, NeutralizingAntibodies, Viralenv Gene Products, Human Immunodeficiency Virusgp140 envelope protein, Human immunodeficiency virus 1gp41 protein, Human immunodeficiency virus 1HIV Envelope Protein gp120HIV Envelope Protein gp41Recombinant Proteins

Identifiers

PMID24179159
PMCPMC3886632
OpenAlexW2000885937

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.